DEMERX
DemeRx develops treatment for drug addiction among patients coping with chronic pain. The company was incorporated in 2010 and is based in Destin, Florida.
DEMERX
Industry:
Health Care Health Diagnostics Medical
Founded:
2010-01-01
Address:
Destin, Florida, United States
Country:
United States
Website Url:
http://www.demerx.com
Total Employee:
11+
Status:
Active
Contact:
(850) 650-1010
Total Funding:
489.57 K USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Apache Global Site Tag
Similar Organizations
Ancora Heart
Ancora Heart is dedicated to helping people with heart failure feel better and live longer.
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Knopp Biosciences
Knopp Neurosciences is a drug discovery and development company working on treatments for neurological disorders.
Pacylex
Pacylex Pharmaceuticals develops a precision medicine solution for multiple common cancers.
Current Employees Featured
Founder
Key Employee Changes
Date | New article |
---|---|
2021-02-05 | PE-backed Blaze Pizza taps Demery as CTO |
Official Site Inspections
http://www.demerx.com Semrush global rank: 4.49 M Semrush visits lastest month: 2.4 K
- Host name: li1038-203.members.linode.com
- IP address: 45.33.96.203
- Location: Atlanta United States
- Latitude: 33.7485
- Longitude: -84.3871
- Metro Code: 524
- Timezone: America/New_York
- Postal: 30301
More informations about "DemeRx"
Team โ DemeRx
In 2010, she founded DemeRx with Steve Gorlin to advance clinical development of the metabolite of ibogaine โ Noribogaine. Deborah served as Director and Chief Scientific Officer โฆSee details»
About โ DemeRx
DemeRx plans to develop a daily dose formulation of DMX-1001 (Noribogaine) for the treatment of alcohol use disorder. DemeRx offers licensing of intellectual property in the field of pharmaceuticals. Bridging the research to clinical โฆSee details»
DemeRx - Psychedelic Science Review
DemeRx. DemeRx is a pharmaceutical company focused on develop ing the psychedelic drug ibogaine and its metabolite noribogaine to treat opioid addiction. The company was founded in โฆSee details»
DemeRx - Crunchbase Company Profile & Funding
Organization. DemeRx . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. DemeRx, Inc. develops treatment for drug โฆSee details»
DemeRx - LinkedIn
DemeRx is excited to announce that Deborah Mash, our CEO, will join global decision makers in life sciences at the Longwood Healthcare Leaders #BostonCEO conference event, on October โฆSee details»
DemeRx, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Jul 1, 2023 Explore DemeRx, Inc. with its drug pipeline, therapeutic area, technology platform, 4 clinical trials, 7 news, and 7 literature, Technology Platform:Small molecule ...See details»
DemeRx - Facebook
DemeRx. 592 likes. The DemeRx organization is the fulfilled vision of Deborah C. Mash, PhD. Dr. Mash is arguably the most knowledgeable and foremost expert on the topic of Ibogaine and Noribogaine...See details»
DemeRx Company Profile 2024: Valuation, Investors, Acquisition
DemeRx General Information Description. Operator of a clinical-stage pharmaceutical development company intended for patients suffering from opioid use disorder. The company โฆSee details»
DemeRx - Overview, News & Similar companies | ZoomInfo.com
DemeRx Doses First Subject in Phase 1/2a Study of DMX-1002 (Ibogaine) in Opioid Use Disorder NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- DemeRx IB, Inc. ("DemeRx"), an atai โฆSee details»
DemeRx Company Profile - Office Locations, Competitors, โฆ
DemeRx is a pharmaceutical development company specializing in medication-assisted therapies for opioid addiction. Its lead drug lbogaine is an indole alkaloid that blocks opioid withdrawal โฆSee details»
DemeRx CEO and Key Executive Team | Craft.co
DemeRx's Executive Chairman is Richard S. Serbin. Other executives include Deborah C. Mash, Chief Executive Officer & Founder, Director; Pascal J. Goldschmidt, Chief Medical Officer, โฆSee details»
Noribogaine - DemeRx
DemeRx has secured GMP drug supplies of noribogaine and the company stands ready to work with government and industry partners to address the worldwide alcohol abuse problem. โฆSee details»
DemeRx - Contacts, Employees, Board Members, Advisors
Organization. DemeRx . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 1. Contacts 4. ... DemeRx โฆSee details»
DemeRx Doses First Subject in Phase 1/2a Study of DMX-1002 โฆ
NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- DemeRx IB, Inc. ("DemeRx"), an atai Life Sciences (Nasdaq: ATAI) ("atai") platform company focused on developing ibogaine for the โฆSee details»
DemeRx 'forging ahead' with atai Life Sciences to dose patients in ...
Oct 12, 2021 DemeRx IB, Inc. CEO Deborah Mash joined Proactive New York to discuss the group's joint venture with Atai Life Sciences (NASDAQ:ATAI), focused on developing ibogaine โฆSee details»
DemeRx Doses First Subject in Phase 1/2a Study of DMX-1002
Sep 21, 2021 About DemeRx, Inc. & DMX-1002 DemeRx, Inc. is a Miami-based clinical stage pharmaceutical company focused on developing ibogaine and noribogaine for the treatment of โฆSee details»
10 Psychedelics CEOs To Pay Attention To In 2022 โ DemeRx
Sep 6, 2022 He has led both ASX listed and privately held businesses, delivering products and services through both SaaS and traditional technology platforms in B2B and B2C โฆSee details»
DemeRx Doses First Subject in Phase 1/2a Study of DMX-1002 โฆ
NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) โ DemeRx IB, Inc. (โDemeRxโ), an atai Life Sciences (Nasdaq: ATAI) (โataiโ) platform company focused on developing ibogaine for the โฆSee details»
News - DemeRx
Jun 26, 2024 Opium Addiction Market expected to rise โ BioCorRx Inc, Delpor Inc, DemeRx Inc, Alar Pharmaceuticals, expected to drive market July 26, 2023 Jun 09, 2023 (AB Digital via โฆSee details»